학술논문
Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults
Document Type
Article
Author
van der Boor, Saskia C ; Smit, Merel J ; van Beek, Stijn W; Ramjith, Jordache; Teelen, Karina; van de Vegte-Bolmer, Marga; van Gemert, Geert-Jan; Pickkers, Peter; Wu, Yimin; Locke, Emily; Lee, Shwu-Maan; Aponte, John; King, C Richter; Birkett, Ashley J; Miura, Kazutoyo; Ayorinde, Morolayo A; Sauerwein, Robert W; ter Heine, Rob; Ockenhouse, Christian F; Bousema, Teun; Jore, Matthijs M; McCall, Matthew B B
Source
In The Lancet Infectious Diseases November 2022 22(11):1596-1605
Subject
Language
ISSN
1473-3099